1
|
Nanoparticles in sentinel lymph node assessment in breast cancer. Cancers (Basel) 2010; 2:1884-94. [PMID: 24281206 PMCID: PMC3840452 DOI: 10.3390/cancers2041884] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Revised: 11/02/2010] [Accepted: 11/09/2010] [Indexed: 02/05/2023] Open
Abstract
The modern management of the axilla in breast cancer relies on surgery for accurate staging of disease and identifying those patients at risk who would benefit from adjuvant chemotherapy. The introduction of sentinel lymph node biopsy has revolutionized axillary surgery, but still involves a surgical procedure with associated morbidity in many patients with no axillary involvement. Nanotechnology encompasses a broad spectrum of scientific specialities, of which nanomedicine is one. The potential use of dual-purpose nanoprobes could enable imaging the axilla simultaneous identification and treatment of metastatic disease. Whilst most applications of nanomedicine are still largely in the laboratory phase, some potential applications are currently undergoing clinical evaluation for translation from the bench to the bedside. This is an exciting new area of research where scientific research may become a reality.
Collapse
|
2
|
Abstract
Colorectal carcinoma continues to be a leading cause of cancer morbidity and mortality despite widespread adoption of screening methods. Targeted detection and therapy using recent advances in our knowledge of in vivo cancer biomarkers promise to significantly improve methods for early detection, risk stratification, and therapeutic intervention. The behavior of molecular targets in transformed tissues is being comprehensively assessed using new techniques of gene expression profiling and high throughput analyses. The identification of promising targets is stimulating the development of novel molecular probes, including significant progress in the field of activatable and peptide probes. These probes are being evaluated in small animal models of colorectal neoplasia and recently in the clinic. Furthermore, innovations in optical imaging instrumentation are resulting in the scaling down of size for endoscope compatibility. Advances in target identification, probe development, and novel instruments are progressing rapidly, and the integration of these technologies has a promising future in molecular medicine.
Collapse
Affiliation(s)
- Pei-Lin Hsiung
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA USA, 94305
| | - Thomas Wang
- Division of Gastroenterology and Hepatology, University of Michigan School of Medicine, Ann Arbor, MI USA, 48109
| |
Collapse
|
3
|
Abstract
JAA-F11 antibody (Ab) is a monoclonal Ab that is specific for the Thomsen-Friedenreich antigen, Galbeta1-3GalNAcalpha (TF-Ag). TF-Ag, discovered in the late 1920s, is a tumor-associated carbohydrate Ag of many clinically widespread carcinomas. In a mouse model, JAA-F11 Ab significantly extended median survival time of animals with metastatic 4T1 breast tumors and caused > 50% inhibition of lung metastasis. (124)Iodine labeled JAA-F11 Ab in in vivo micro positron emission tomography showed tumor specificity in a mouse breast tumor model, with no preferential uptake by any other organ. Human cancer cell adhesion to vascular endothelium was also blocked by JAA-F11. Structural specificity of the Ab was shown with glycan array analysis and indicated that this Ab, unlike many other Abs to TF-Ag, will not bind to a related glycolipid on natural killer cells, kidney or spleen. Patients with higher levels of naturally occurring anti-TF-Ag Ab appear to have a better prognosis, indicating that passive transfer of JAA-F11 or active immunization, resulting in production of anti-TF-Ag Ab, would clinically be beneficial for the patient.
Collapse
Affiliation(s)
- Kate Rittenhouse-Olson
- University at Buffalo, Department of Biotechnical and Clinical Laboratory Sciences, Buffalo, NY 14214, USA.
| |
Collapse
|
4
|
Chaturvedi R, Heimburg J, Yan J, Koury S, Sajjad M, Abdel-Nabi HH, Rittenhouse-Olson K. Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen. Appl Radiat Isot 2007; 66:278-87. [PMID: 17890096 PMCID: PMC3192430 DOI: 10.1016/j.apradiso.2007.07.029] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2007] [Revised: 05/18/2007] [Accepted: 07/05/2007] [Indexed: 10/22/2022]
Abstract
Clinical immunolocalization has been attempted by others with an anti-Thomsen-Friedenreich antigen (TF-Ag) mAb that bound both alpha- and beta-linked TF-Ag. In this report, 124 I-labeled mAb JAA-F11 specific for alpha-linked TF-Ag showed higher tumor specificity in in vivo micro-positron emission tomography (micro-PET) of the mouse mammary adenocarcinoma line, 4T1, showing no preferential uptake by the kidney. Labeled product remained localized in the tumor for at least 20 days. Glycan array analysis showed structural specificity of the antibody.
Collapse
Affiliation(s)
- Richa Chaturvedi
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Jamie Heimburg
- Department of Microbiology and Immunology, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Jun Yan
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Stephen Koury
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Munawwar Sajjad
- Department of Nuclear Medicine, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Hani H Abdel-Nabi
- Department of Nuclear Medicine, University at Buffalo, the State University of New York, Buffalo, New York 14214
| | - Kate Rittenhouse-Olson
- Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, the State University of New York, Buffalo, New York 14214
- Department of Microbiology and Immunology, University at Buffalo, the State University of New York, Buffalo, New York 14214
- Corresponding author: Kate Rittenhouse-Olson, 26 Cary Hall, 3435 Main St, Buffalo NY 14214, 716-829-3630 x116, fax 716-829-3601,
| |
Collapse
|
5
|
Heimburg J, Yan J, Morey S, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, Glinsky VV, Rittenhouse-Olson K. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia 2007; 8:939-48. [PMID: 17132226 PMCID: PMC1716011 DOI: 10.1593/neo.06493] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Thomsen-Friedenreich antigen (TF-Ag) is expressed in many carcinomas, including those of the breast, colon, bladder, and prostate. TF-Ag is important in adhesion and metastasis and as a potential immunotherapy target. We hypothesized that passive transfer of JAA-F11, an anti-TF-Ag monoclonal antibody, may create a survival advantage for patients with TF-Ag-expressing tumors by cytotoxicity, blocking of tumor cell adhesion, and inhibition of metastasis. This was tested using in vitro models of tumor cell growth; cytotoxicity assays; in vitro, ex vivo, and in vivo models of cancer metastasis; and, finally, in vivo effects in mice with metastatic breast cancer. Unlike some anti-TF-Ag antibodies, JAA-F11 did not enhance breast carcinoma cell growth. JAA-F11 did not induce the killing of 4T1 tumor cells through complement-dependent cytotoxicity or apoptotic mechanisms. However, JAA-F11 blocked the stages of metastasis that involve the adhesion of human breast carcinoma cells to human endothelial cells (human umbilical vein endothelial cells and human bone marrow endothelial cells 60) in in vitro static adhesion models, in a perfused ex vivo model, and in murine lung vasculature in an in vivo metastatic deposit formation assay. JAA-F11 significantly extended the median survival time of animals bearing metastatic 4T1 breast tumors and caused a > 50% inhibition of lung metastasis.
Collapse
Affiliation(s)
- Jamie Heimburg
- Department of Microbiology and Immunology, The University at Buffalo, Buffalo, NY 14214, USA
| | - Jun Yan
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Susan Morey
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Olga V Glinskii
- Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65211, USA
| | - Virginia H Huxley
- Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65211, USA
| | - Linda Wild
- Department of Pathology and Anatomical Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Robert Klick
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| | - Rene Roy
- Department of Chemistry, University of Quebec at Montreal, Montreal, Quebec, Canada H3C 3P8
| | - Vladislav V Glinsky
- Department of Biochemistry, University of Missouri, Columbia, MO 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, MO 65201, USA
| | - Kate Rittenhouse-Olson
- Department of Microbiology and Immunology, The University at Buffalo, Buffalo, NY 14214, USA
- Department of Biotechnical and Clinical Laboratory Sciences, The University at Buffalo, Buffalo, NY 14214, USA
| |
Collapse
|
6
|
Lu JY, Chen HC, Chu RYY, Lin TCE, Hsu PI, Huang MS, Tseng CJ, Hsiao M. Establishment of red fluorescent protein-tagged HeLa tumor metastasis models: determination of DsRed2 insertion effects and comparison of metastatic patterns after subcutaneous, intraperitoneal, or intravenous injection. Clin Exp Metastasis 2003; 20:121-33. [PMID: 12705633 DOI: 10.1023/a:1022645116030] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Metastasis is the leading cause of death in patients with cervical cancer. In this report, we establish novel fluorescent HeLa tumor metastasis models to determine whether HeLa transfected with the enhanced red fluorescent protein (DsRed2) gene in vitro and xenotransplanted through subcutaneous, intraperitoneal, or intravenous route into SCID mice would permit the detection of tumor micro-metastasis in vivo. Our results showed that DsRed2 insertions did not interfere the tumorigenic properties of HeLa cells. We also demonstrated that DsRed2-transduced HeLa cells maintained stable high-level DsRed2 expressions during their growth in vivo. DsRed2 fluorescence clearly demarcated the primary seeding place and readily allowed for the visualization of distant micro-metastasis and local invasion at the single-cell level. Lung metastasis, the major cause of cervical carcinoma related death, was found in all three models. However, intravenous injections of the HeLa-DsRed2 cells established tumor foci in the lung, while subcutaneous and intraperitoneal injections only established lung metastasis at single-cell levels. The DsRed2 tagged HeLa cancer model allowed detection and investigation of physiologically relevant patterns of cancer invasion and metastasis in vivo.
Collapse
Affiliation(s)
- Jau-Yeong Lu
- Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Affiliation(s)
- R M Hoffman
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA 92111, USA.
| |
Collapse
|
8
|
Huang MS, Wang TJ, Liang CL, Huang HM, Yang IC, Yi-Jan H, Hsiao M. Establishment of fluorescent lung carcinoma metastasis model and its real-time microscopic detection in SCID mice. Clin Exp Metastasis 2002; 19:359-68. [PMID: 12090477 DOI: 10.1023/a:1015562532564] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Lung cancer is the most prevalent malignant tumor in the world. Metastasis of the disease causes death in lung cancer patients. Recent study has shown that multiple cascades of gene defects occur in lung cancer. In this report, we established a novel H1299/EGFP tumor model to determine whether H1299 transfected with the enhanced green fluorescent protein (EGFP) gene in vitro and xenotransplanted into SCID mouse lung would permit the detection of lung cancer micrometastasis in vivo. We demonstrated that EGFP-transduced H1299 cells maintained stable high-level EGFP expressions during their growth in vivo. EGFP fluorescence clearly demarcated the primary seeding place and readily allowed for the visualization of distant micrometastasis and local invasion at the single-cell level. Small metastatic and locally invasive foci, including those immediately adjacent to the tumor's leading invasive edge, were almost undetectable by routine hematoxylin and eosin staining and immunohistochemistry. The GFP tagged lung cancer model is superior for the detection and study of physiologically relevant patterns of lung cancer invasion and metastasis in vivo.
Collapse
Affiliation(s)
- Ming-Shyan Huang
- Department of Internal Medicine, Kaohsiung Medical University, Taiwan
| | | | | | | | | | | | | |
Collapse
|
9
|
Reilly RM, Maiti PK, Kiarash R, Prashar AK, Fast DG, Entwistle J, Narang SA, Foote S, Kaplan HA. Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In. Nucl Med Commun 2001; 22:587-95. [PMID: 11388583 DOI: 10.1097/00006231-200105000-00019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
H11 is a human IgM monoclonal antibody which recognizes a novel tumour-associated antigen expressed on melanoma, glioma, breast cancer, colon cancer, prostate cancer, lung cancer and B-cell lymphoma. In this study, a recombinant single-chain Fv (scFv) fragment of H11 labelled with 111In was investigated for tumour imaging in athymic mice implanted subcutaneously with A-375 human melanoma xenografts. H11 scFv was derivatized with diethylenetriaminepentaacetic acid (DTPA) for labelling with 111In. The immunoreactivity of DTPA-H11 scFv against A-375 cells in vitro ranged from 23% to 36%. 111In-DTPA-H11 scFv was rapidly eliminated from the blood and most normal tissues (except the kidneys) reaching maximum tumour/blood ratios of 12:1 at 48 h post-injection. Tumours were imaged as early as 40 min after injection. The kidneys accumulated the highest concentration of radioactivity (up to 185% injected dose/g). Tumour uptake was 1-3% injected dose/g. The whole-body radiation absorbed dose predicted for administration of 185 MBq of 111In-DTPA-H11 scFv to humans was 37 mSv. The radiation absorbed dose estimates for the kidneys, spleen and intestines were 405 mSv, 698 mSv and 412 mSv, respectively. The results of this preclinical study and a concurrent phase I trial suggest a promising role for H11 scFv for tumour imaging.
Collapse
Affiliation(s)
- R M Reilly
- Division of Nuclear Medicine, Toronto General Hospital, University Health Network, ON, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Yang M, Baranov E, Jiang P, Sun FX, Li XM, Li L, Hasegawa S, Bouvet M, Al-Tuwaijri M, Chishima T, Shimada H, Moossa AR, Penman S, Hoffman RM. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A 2000; 97:1206-11. [PMID: 10655509 PMCID: PMC15570 DOI: 10.1073/pnas.97.3.1206] [Citation(s) in RCA: 332] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
We have imaged, in real time, fluorescent tumors growing and metastasizing in live mice. The whole-body optical imaging system is external and noninvasive. It affords unprecedented continuous visual monitoring of malignant growth and spread within intact animals. We have established new human and rodent tumors that stably express very high levels of the Aequorea victoria green fluorescent protein (GFP) and transplanted these to appropriate animals. B16F0-GFP mouse melanoma cells were injected into the tail vein or portal vein of 6-week-old C57BL/6 and nude mice. Whole-body optical images showed metastatic lesions in the brain, liver, and bone of B16F0-GFP that were used for real time, quantitative measurement of tumor growth in each of these organs. The AC3488-GFP human colon cancer was surgically implanted orthotopically into nude mice. Whole-body optical images showed, in real time, growth of the primary colon tumor and its metastatic lesions in the liver and skeleton. Imaging was with either a trans-illuminated epifluorescence microscope or a fluorescence light box and thermoelectrically cooled color charge-coupled device camera. The depth to which metastasis and micrometastasis could be imaged depended on their size. A 60-microm diameter tumor was detectable at a depth of 0.5 mm whereas a 1, 800-microm tumor could be visualized at 2.2-mm depth. The simple, noninvasive, and highly selective imaging of growing tumors, made possible by strong GFP fluorescence, enables the detailed imaging of tumor growth and metastasis formation. This should facilitate studies of modulators of cancer growth including inhibition by potential chemotherapeutic agents.
Collapse
Affiliation(s)
- M Yang
- AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA 92111, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Weissleder R, Tung CH, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999; 17:375-8. [PMID: 10207887 DOI: 10.1038/7933] [Citation(s) in RCA: 1107] [Impact Index Per Article: 44.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We have developed a method to image tumor-associated lysosomal protease activity in a xenograft mouse model in vivo using autoquenched near-infrared fluorescence (NIRF) probes. NIRF probes were bound to a long circulating graft copolymer consisting of poly-L-lysine and methoxypolyethylene glycol succinate. Following intravenous injection, the NIRF probe carrier accumulated in solid tumors due to its long circulation time and leakage through tumor neovasculature. Intratumoral NIRF signal was generated by lysosomal proteases in tumor cells that cleave the macromolecule, thereby releasing previously quenched fluorochrome. In vivo imaging showed a 12-fold increase in NIRF signal, allowing the detection of tumors with submillimeter-sized diameters. This strategy can be used to detect such early stage tumors in vivo and to probe for specific enzyme activity.
Collapse
Affiliation(s)
- R Weissleder
- Center of Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
| | | | | | | |
Collapse
|